California Paid Clinical Trials

A listing of 5615 clinical trials in California actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Clinical Trials

California

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Location

Filter by Age

California is currently home to 5615 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Total RadIoTherapy of Oligometastatic CaNcerS

NCT06587490

Recruiting

This is a Phase III non-blinded randomized study evaluating patients with oligometastatic cancers (up to 10 metastases). Subjects are randomized 1:1 to stereotactic ablative radiotherapy (SABR) plus standard of care therapies versus SABR alone. The investigators will measure progression-free survival at 2 years based on the hypothesis that subjects treated with SABR plus standard of care will not experience disease progression for a longer period of time than subjects treated with standard of ca... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: University of California San Diego, La Jolla, California

Conditions: Oligometastatic Malignant Solid Neoplasm

Learn More ›

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

NCT06561152

Recruiting

To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: Stanford University, Palo Alto, California

Conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia

Learn More ›

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years with ADHD

NCT06431256

Recruiting

This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.

Gender:

ALL

Ages:

Between 4 years and 5 years

Trial Updated:

03/14/2025

Locations: HLD200-112 Study Site, Anaheim, California

Conditions: Attention Deficit Hyperactivity Disorder

Learn More ›

IHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults with Type 1 Diabetes

NCT06348160

Recruiting

This research study aims to test a financial and health insurance iHERO Toolkit for young adults with type1 diabetes. The iHERO Toolkit was developed over one year with the type 1 diabetes community, The Diabetes Link organization, and experts. Now, the investigators want to understand the impact of the iHERO Toolkit on diabetes self-management, financial stress, and health insurance literacy outcomes. The investigators are doing this study because it will help to better understand how to suppor... Read More

Gender:

ALL

Ages:

Between 18 years and 30 years

Trial Updated:

03/14/2025

Locations: Children's Hospital Los Angeles, Los Angeles, California

Conditions: Type 1 Diabetes

Learn More ›

Prospective Study of oncRNA Stratification of Cancer by Size and Stage

NCT05833360

Recruiting

Cancer strikes about one in three women and one in two men in the U.S. and more than 600,000 die from it each year. The best chance to reduce these numbers and save lives is through early detection and intervention. The investigators are developing a blood test to detect cancer from a simple blood draw also referred to as a liquid biopsy. This test is based on orphan non-coding RNAs (oncRNAs) that are abundant in the blood of patients with cancer and largely absent in people without cancer. Using artificial intelligence (AI) and machine learning (ML) investigators are able to interpret the thousands of oncRNAs found in the blood of patients with cancer by identifying unique, cancer-specific patterns. oncRNA patterns can be used to detect several types of cancer and detect cancer at the earliest stages. This is a prospective, observational study to collect blood samples and medical information from participants with and without cancer to represent the population in the USA. The investigators have designed the study to include participants without cancer, participants with conditions that are a predisposition for cancer, participants with pre-malignant lesions, and participants with cancer. Patients with a wide variety of cancers are going to be included i.e. bladder, breast, colorectal, esophageal, gastric, kidney, liver, lung, ovarian, pancreatic, prostate, and uterine cancer. Each participant will be asked to donate a small blood sample and to share their medical information. The participant's medical information will be updated during the course of the study. The blood will be tested for oncRNA. The objective is to create a blood repository and associated medical database to develop a blood test for cancer, for different cancer types. The study is designed to be inclusive and represent the population in America. If this study is successful, the results will enable a world where cancer can be detected early with a simple blood test and diagnosed accurately, with better chances of cure. The investigators believe this study has the potential to transform cancer detection in America. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: Exai Bio Inc., Palo Alto, California

Conditions: Cancer

Learn More ›

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

NCT05677880

Recruiting

This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: University of California, Los Angeles, California

Conditions: CADASIL

Learn More ›

The DISCOVER INOCA Prospective Multi-center Registry

NCT05288361

Recruiting

The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: UCLA Health, Los Angeles, California

Conditions: Ischemia and no Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography

Learn More ›

A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer

NCT05226507

Recruiting

The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: UC San Diego Health - Moores Cancer Center, La Jolla, California

Conditions: Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation

Learn More ›

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

NCT04422912

Recruiting

A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: Stanford University, Dept. of Dermatology, Redwood City, California

Conditions: Pemphigus Vulgaris

Learn More ›

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596

Recruiting

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expressing advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma patients. Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or immunotherapy administered to subjects at the recommended phase 2 dose will sho... Read More

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

03/14/2025

Locations: Research Site, Santa Monica, California

Conditions: Gastric Cancer

Learn More ›

Study of DF1001 in Patients with Advanced Solid Tumors

NCT04143711

Recruiting

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eli... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/14/2025

Locations: University of California Irvine Medical Center, Irvine, California

Conditions: Solid Tumor, Adult

Learn More ›

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT03802695

Recruiting

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

03/14/2025

Locations: City of Hope, Duarte, California

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia

Learn More ›

Kaiser Permanente houses over 6,000 physicians in southern California and it is also one of the largest research centers on the state. On its clinical trial division, Kaiser Permanente conducts clinical trials of almost every specialty funded by pharmaceutical companies, government, and foundations.

The Cedars-Sinai Medical Center located in Los Angeles is one of the largest research centers owned and operated by a private hospital in the United States. Focusing on biomedical, cancer, and heart research among other specialties, you can find almost any type of clinical trials for both health and non-healthy volunteers at the research division of Cedar-Sinai Medical Center.

There are around 100,000 clinical trials happening every year across the United States about almost every condition out there. While most clinical trials are testing drugs or medical devices there are also many behavioral and observational trials going on at any point in time. Many paid research studies are held at these California locations.

Clinical trials are incredibly important for making new medical and scientific discoveries, finding new and better methods for diagnosing medical conditions early, testing new interventions, and even developing safer and more effective surgical procedures.

In order for all these discoveries to me made available to the general population they need to go through years of rigorous testing both in healthy and non-healthy volunteers. During those years, medical professionals follow a protocol that has been previously approved by the FDA or other regulatory agency to test the effectiveness and safety of their discovery.

Other people choose to participate in a clinical trial because they feel it is a good way to contribute to the advancement of medical knowledge and that their participation can help many people in the future. The following lists of trials are broken down by condition, and to find a specific clinical trial in your area click through to clinicaltrials.gov.